Literature DB >> 1378022

Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.

M Kuraya1, E Yefenof, G Klein, E Klein.   

Abstract

On a panel of nine human B cell lines we showed that the expression of the complement regulatory factors complement receptor type 2 (CR2; CD21), decay-accelerating factor, (DAF; CD55) and homologous restriction factor (HRF20, CD59) is not correlated. All lines expressed DAF, six lines carried detectable amounts of CR2 and three carried HRF20. Upon incubation in human serum, under conditions which allowed the activation of complement through the alternative pathway, the CR2-carrying lines bound C3 fragments and two of them (Ramos and one of its two sublines) were damaged. These two lines had the lowest DAF expression, less than 50% of the cells reacted with the IA10 monoclonal antibody. By modulating the expression of the complement regulatory molecules, the lytic sensitivity of the B cell lines could be altered. Blockade of DAF on the HRF20-, CR2+ lines with the specific monoclonal antibodies increased their sensitivity to lysis by human serum. With the DAF- and HRF20+ cells significant lytic effect was obtained only when they were pretreated with both of the specific antibodies. Interferon-gamma or tumor necrosis factor-alpha treatment elevated the amount of CR2 on the low-CR2 expressor line (Ramos/HR1K) which thereafter bound higher amounts of C3 fragments and was lysed when incubated in human serum. This line had relatively low DAF level and lacked HRF20. The cytokine treatment did not alter the expression of these molecules. The CR2+ Ramos and the CR2- Rael cells were treated with 5-azacytidine which induced HRF20 and increased DAF expression. In parallel with this change Ramos cells became resistant to C-mediated lysis. The experiments with the panel of human B cell lines showed thus that cytolysis through activation of complement in homologous serum can be regulated at several steps by cell surface molecules. While expression of CR2 was required for C3 fixation, DAF and HRF20 inhibited lysis. By independent modulation of the quantities of these molecules, cells acquired or lost their sensitivity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378022     DOI: 10.1002/eji.1830220729

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

2.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

4.  Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.

Authors:  L Baranyi; K Baranji; H Takizawa; N Okada; H Okada
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

5.  Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.

Authors:  C L Harris; B P Morgan
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

Review 6.  Beyond the Role of CD55 as a Complement Component.

Authors:  So Hee Dho; Jae Cheong Lim; Lark Kyun Kim
Journal:  Immune Netw       Date:  2018-02-20       Impact factor: 5.851

Review 7.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

Review 8.  The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.

Authors:  Anne Geller; Jun Yan
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

9.  Integrative Analysis of Complement System to Prognosis and Immune Infiltrating in Colon Cancer and Gastric Cancer.

Authors:  Dandan Bao; Chenghao Zhang; Longlong Li; Haihong Wang; Qiuyan Li; Leilei Ni; Yinfeng Lin; Rong Huang; Zhangwei Yang; Yan Zhang; Yiren Hu
Journal:  Front Oncol       Date:  2021-02-03       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.